[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100591761":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":28,"centralContacts":29,"locations":36,"responsibleParty":191,"collaborators":28,"id":193,"slug":194,"hasResults":195,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":28,"eligibilityCriteria":199,"healthyVolunteers":195,"sex":200,"minAge":201,"maxAge":202,"enrollmentInfo":203,"targetDuration":28,"studyType":206,"phases":207,"briefSummary":209,"conditions":210,"keywords":28,"overallStatus":39,"whyStopped":28,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":221},{"fullName":5,"class":6},"Sanofi","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Rilzabrutinib dose 1","EXPERIMENTAL","Rilzabrutinib",[13],"Drug: Rilzabrutinib dose 1",{"label":15,"type":10,"description":11,"interventionNames":16},"Rilzabrutinib dose 2",[17],"Drug: Rilzabrutinib dose 2",[19,25],{"type":20,"name":9,"description":21,"armGroupLabels":22,"otherNames":23},"DRUG","Pharmaceutical form:Tablet-Route of administration:Oral",[9],[24],"SAR444671",{"type":20,"name":15,"description":21,"armGroupLabels":26,"otherNames":27},[15],[24],null,[30],{"name":31,"role":32,"phone":33,"phoneExt":34,"email":35},"Trial Transparency email recommended (Toll free for US & Canada)","CONTACT","800-633-1610","option 6","Contact-US@sanofi.com",[37,51,61,71,82,91,103,113,119,128,137,149,159,169,181],{"facility":38,"status":39,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":28},"Investigational Site Number : 1240003","RECRUITING","Calgary","Alberta","T2N 4L7","Canada","CA",{"type":46,"coordinates":47},"Point",[48,49],-114.08529,51.05011,{"lat":49,"lon":48},{"facility":52,"status":39,"city":53,"state":54,"zip":55,"country":43,"countryCode":44,"cosmosGeoPoint":56,"geoPoint":60,"contacts":28},"Investigational Site Number : 1240002","Surrey","British Columbia","V3T 4G8",{"type":46,"coordinates":57},[58,59],-122.82509,49.10635,{"lat":59,"lon":58},{"facility":62,"status":39,"city":63,"state":64,"zip":65,"country":43,"countryCode":44,"cosmosGeoPoint":66,"geoPoint":70,"contacts":28},"Investigational Site Number : 1240001","Sherbrooke","Quebec","J1H 5N4",{"type":46,"coordinates":67},[68,69],-71.89908,45.40008,{"lat":69,"lon":68},{"facility":72,"status":39,"city":73,"state":28,"zip":74,"country":75,"countryCode":76,"cosmosGeoPoint":77,"geoPoint":81,"contacts":28},"Investigational Site Number : 2760002","Essen","45147","Germany","DE",{"type":46,"coordinates":78},[79,80],7.01228,51.45657,{"lat":80,"lon":79},{"facility":83,"status":39,"city":84,"state":28,"zip":85,"country":75,"countryCode":76,"cosmosGeoPoint":86,"geoPoint":90,"contacts":28},"Investigational Site Number : 2760001","Frankfurt","60590",{"type":46,"coordinates":87},[88,89],10.53333,49.68333,{"lat":89,"lon":88},{"facility":92,"status":39,"city":93,"state":94,"zip":95,"country":96,"countryCode":97,"cosmosGeoPoint":98,"geoPoint":102,"contacts":28},"Investigational Site Number : 3800005","Merano","Bolzano \u002F Bozen","39100","Italy","IT",{"type":46,"coordinates":99},[100,101],11.15953,46.66817,{"lat":101,"lon":100},{"facility":104,"status":39,"city":105,"state":106,"zip":107,"country":96,"countryCode":97,"cosmosGeoPoint":108,"geoPoint":112,"contacts":28},"Investigational Site Number : 3800001","Milan","Milano","20122",{"type":46,"coordinates":109},[110,111],9.18951,45.46427,{"lat":111,"lon":110},{"facility":114,"status":39,"city":105,"state":106,"zip":115,"country":96,"countryCode":97,"cosmosGeoPoint":116,"geoPoint":118,"contacts":28},"Investigational Site Number : 3800004","20132",{"type":46,"coordinates":117},[110,111],{"lat":111,"lon":110},{"facility":120,"status":39,"city":121,"state":28,"zip":122,"country":96,"countryCode":97,"cosmosGeoPoint":123,"geoPoint":127,"contacts":28},"Investigational Site Number : 3800003","Palermo","90127",{"type":46,"coordinates":124},[125,126],13.3636,38.1166,{"lat":126,"lon":125},{"facility":129,"status":39,"city":130,"state":28,"zip":131,"country":96,"countryCode":97,"cosmosGeoPoint":132,"geoPoint":136,"contacts":28},"Investigational Site Number : 3800002","Pisa","56126",{"type":46,"coordinates":133},[134,135],10.4036,43.70853,{"lat":135,"lon":134},{"facility":138,"status":39,"city":139,"state":140,"zip":141,"country":142,"countryCode":143,"cosmosGeoPoint":144,"geoPoint":148,"contacts":28},"Investigational Site Number : 7240002","Barcelona","Catalunya [Cataluña]","08036","Spain","ES",{"type":46,"coordinates":145},[146,147],2.15899,41.38879,{"lat":147,"lon":146},{"facility":150,"status":39,"city":151,"state":152,"zip":153,"country":142,"countryCode":143,"cosmosGeoPoint":154,"geoPoint":158,"contacts":28},"Investigational Site Number : 7240001","Pamplona","Navarre","31008",{"type":46,"coordinates":155},[156,157],-1.64323,42.81687,{"lat":157,"lon":156},{"facility":160,"status":39,"city":161,"state":162,"zip":163,"country":142,"countryCode":143,"cosmosGeoPoint":164,"geoPoint":168,"contacts":28},"Investigational Site Number : 7240004","Seville","Sevilla","41009",{"type":46,"coordinates":165},[166,167],-5.97317,37.38283,{"lat":167,"lon":166},{"facility":170,"status":39,"city":171,"state":172,"zip":173,"country":174,"countryCode":175,"cosmosGeoPoint":176,"geoPoint":180,"contacts":28},"Investigational Site Number : 8260003","Milton Keynes","Buckinghamshire","MK6 5LD","United Kingdom","UK",{"type":46,"coordinates":177},[178,179],-0.75583,52.04172,{"lat":179,"lon":178},{"facility":182,"status":39,"city":183,"state":184,"zip":185,"country":174,"countryCode":175,"cosmosGeoPoint":186,"geoPoint":190,"contacts":28},"Investigational Site Number : 8260001","Newcastle upon Tyne","England","NE2 4HH",{"type":46,"coordinates":187},[188,189],-1.61396,54.97328,{"lat":189,"lon":188},{"type":192,"investigatorFullName":28,"investigatorTitle":28,"investigatorAffiliation":28,"oldNameTitle":28,"oldOrganization":28},"SPONSOR","100591761","phase-2-a-study-to-investigate-the-efficacy-and-safety-of-rilzabrutinib-in-adult-participants-with-graves-disease-100591761",false,"NCT06984627","A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' Disease","An Open-label Phase 2 Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' Disease","Inclusion Criteria:\n\n* Participants who have a confirmed diagnosis of Graves' disease with active hyperthyroidism, with or without active Graves' orbitopathy at the time of screening.\n* A subset of participants will have a diagnosis of active Graves' orbitopathy, as confirmed by ophthalmic exam at screening and a clinical activity score (CAS) ≥3 for the most severely affected eye, and associated with one or more of the following: lid retraction ≥2 mm, moderate or severe soft tissue involvement, proptosis ≥2 mm, and\u002For intermittent or constant diplopia.\n* Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.\n\nExclusion Criteria:\n\n* History of hyperthyroidism not caused by Graves' disease (eg, hyperthyroidism due to toxic multinodular goiter, autonomous thyroid nodule, acute inflammatory thyroiditis).\n* History of thyroid storm or at high risk of developing thyroid storm as determined by evaluating clinician.\n* Enlarged thyroid goiter causing upper airway obstruction and\u002For requiring surgical intervention during the study period.\n* For participant with Graves' orbitopathy, requires immediate surgical ophthalmological intervention or is planning corrective surgery\u002Firradiation during the course of the study.\n* Sight threatening Graves' orbitopathy or decreased visual acuity due to optic neuropathy within the last 6 months.\n* Corneal decompensation unresponsive to medical management.\n* Onset of Graves' orbitopathy symptoms \\>9 months prior to baseline.\n\nThe above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.","ALL","18 Years","75 Years",{"count":204,"type":205},30,"ESTIMATED","INTERVENTIONAL",[208],"PHASE2","This is a parallel group, Phase 2, 2-arm study to measure the treatment effect and safety of rilzabrutinib dose 1 or rilzabrutinib dose 2 in participants with Graves' disease, with and without Graves' orbitopathy, aged 18 years or older.\n\nStudy details include:\n\n* Screening period (up to 4 weeks).\n* Treatment period (up to 16 weeks).\n* Follow-up period (4 weeks). The number of visits will be up to 13.",[211],"Graves' Disease","2026-07-06",{"date":214,"type":215},"2026-07-07","ACTUAL",{"date":217,"type":215},"2025-09-02",{"date":219,"type":205},"2026-09-23",{"name":5,"class":6},15]